Obesity Featured Articles

  1. The Profit Margin Double Standard That Needs To Change 7/10/2026

    We expect pharmaceutical companies to have sizable profit margins, but we collectively scoff at research sites for achieving the same. Maria P. Ladd explores this difference in expectations and why it needs to change for the sake of the industry.

  2. Why The Governed Hybrid Site Model Is Strategically Superior — Part 3 7/10/2026

    In the third and final part of this series, Paradigm Clinical Research CEO Kurt Mussina, who's become an advocate for the governed hybrid platform, explains why he believes it's the best fit for sponsors.

  3. Beyond The IND Clock: What Operation TrialBlazer Gets Right — And Where It Stalls (Part 1) 7/10/2026

    The FDA's Operation TrailBlazer includes a proposal to speed up IND review and approval. But will it work? Kimberly Chew and Odette Hauke identify where the initiative succeeds and where the structural gaps begin.

  4. Beyond The IND Clock: The Legal Architecture Of QRIs And What Industry Must Say Before July 22 (Part 2) 7/10/2026

    The FDA's Operation TrailBlazer includes a proposal to speed up IND review and approval. But Kimberly Chew and Odette Hauke say its legal architecture is unresolved and reveals compliance issues that are hard to ignore.

  5. Project Management And AI: What Should Be Automated And What Should Not 7/9/2026

    How can clinical research project management be optimize by AI? To determine its best fit, consultant Jason C. Bork assess AI's utility in project management through the lens of Plan, Do, Check, Act (PDCA).

  6. How Clinical Research Site Operating Models Perform in Practice – Part 2 7/9/2026

    In part two of this three-part series, Paradigm Clinical Research CEO Kurt Mussina evaluates how each site operating model performs regarding speed, patient access, investigator engagement, quality, accountability, and scalability.

  7. European Clinical Trial Support Has To Work Country By Country 7/8/2026

    Cross-border trial access looks easy in policy, but patients face real barriers: travel, documents, reimbursement, language. Plan the support model before recruitment begins so eligible patients can actually participate

  8. What To Know About The European Biotech Act 7/8/2026

    EU-X-CT’s Biotech Act leaflet highlights cross-border trial access and the practical support patients need to travel, communicate, get reimbursed, and participate safely in another country.

  9. Flexible By Design: Support For Early-Phase Oncology Trial 7/8/2026

    Shifting cohorts, doses, and protocols challenge early-phase oncology trials. Learn how adaptable technology keeps studies on track.

  10. Responsible AI In Clinical Trials Starts With How It Is Designed 7/8/2026

    Explore how trials can responsibly use AI to move faster while keeping human judgment, data protections, and auditability intact.